Cargando…
Correction: Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
Autores principales: | Sirima, Sodiomon B., Tiono, Alfred B., Ouédraogo, Alphonse, Diarra, Amidou, Ouédraogo, André Lin, Yaro, Jean Baptiste, Ouédraogo, Espérance, Gansané, Adama, Bougouma, Edith C., Konaté, Amadou T., Kaboré, Youssouf, Traoré, Abdoulaye, Roma, Chilengi, Soulama, Issiaka, Luty, Adrian J. F., Druilhe, Pierre, Cousens, Simon, Nébié, Issa |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862746/ http://dx.doi.org/10.1371/annotation/3221b8d9-038d-4e67-82fa-de6b1233b459 |
Ejemplares similares
-
Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
por: Sirima, Sodiomon B., et al.
Publicado: (2009) -
Clinical Variation of Plasmodium falciparum eba-175, ama-1, and msp-3 Genotypes in Young Children Living in a Seasonally High Malaria Transmission Setting in Burkina Faso
por: Soulama, Issiaka, et al.
Publicado: (2015) -
Seasonal performance of a malaria rapid diagnosis test at community health clinics in a malaria-hyperendemic region of Burkina Faso
por: Diarra, Amidou, et al.
Publicado: (2012) -
A Phase 1b Randomized, Controlled, Double-Blinded Dosage-Escalation Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe Healthy Adults 18 to 45 Years of Age
por: Ouédraogo, Alphonse, et al.
Publicado: (2013) -
Intermittent Preventive Treatment of Malaria Provides Substantial Protection against Malaria in Children Already Protected by an Insecticide-Treated Bednet in Burkina Faso: A Randomised, Double-Blind, Placebo-Controlled Trial
por: Konaté, Amadou T., et al.
Publicado: (2011)